BWI-CTU Researchers Elected to ACTG Network Committees

Published Date:

11/30/2016

November 29, 2016—The ACTG Network announced today the results of elections for the network's laboratory, leadership, science, and resource committees. Congratulations to the following BWI-CTU researchers, who were elected to serve for the term of December 1, 2016 – November 30, 2017:

  • Christine Durand, Johns Hopkins Clincial Trials Site (Baltimore)
    Investigator, HIV Reservoirs & Viral Eradication Transformative Science Group.  
     
  • David Hardy, Whitman-Walker Clincial Trials Site (Washington)
    Investigator, HIV Reservoirs & Viral Eradication Transformative Science Group.  
      
  • Ya-Chi Ho, Johns Hopkins Clincial Trials Site (Baltimore)
    Investigator, HIV Reservoirs & Viral Eradication Transformative Science Group.  
      
  • Charles Flexner, Johns Hopkins Clincial Trials Site (Baltimore)
    Non-voting Member, Antiretroviral Therapy Strategies Subcommittee.  
        
  • Vidya Mave, Byramjee Jeejeebhoy Clincial Trials Site (India)
    Investigator, Tuberculosis Transformative Science Group.  
       
  • Eric Nuermberger, Johns Hopkins Clincial Trials Site (Baltimore)
    Investigator, Tuberculosis Transformative Science Group.  
        
  • Ilene Wiggins, Johns Hopkins Clincial Trials Site (Baltimore)
    Chair, Site Management & Clinical Care Committee

Clinical Trials

P1077FF: Formula Feeding Version of the PROMISE Study...

1077FF is a randomized strategy trial, which is part of the PROMISE studies (1077BF, 1077FF, P1084s, and 1077HS). The Promoting...

Read More

A5308: A Prospective, Single-Arm, Open-Label Study to...

This study is being done with people who are infected with HIV, but do not show any signs of having HIV. They are also feeling...

Read More

P1060: Phase II, parallel, randomized, clinical trials...

P1060 is currently at protocol Version 5.0, which is an extension phase of P1060 Version 4.0. P1060 Version 4.0 was a Phase II,...

Read More

A5128: Consent for Use of Stored Patient Specimens for...

The purpose of this study is to obtain informed consent to use stored human biological materials (HBM) (e.g., blood and other...

Read More

A5314: Effect of LDMTX on Inflammation in HIV-infected...

A5314 is a phase II randomized, double-blind, placebo-controlled 36-week trial that will examine the safety and efficacy of...

Read More